Search
Bio-Techne Corp
TECHAdd to Watchlist
57.940USD
+2.940+5.35%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
9.03BMarket Cap
82.10P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Bio-Techne Corp is 7.88, ranking 272 out of 389 in the Biotechnology & Medical Research industry. The average price target is 70.00, with a high of 75.00 and a low of 60.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
62.708
Target Price
+14.02%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Bio-Techne Corp
TECH
17
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Bio-Techne Corp's expected revenue for the next quarter?
Bio-Techne Corp's expected revenue is 314.40M.
What is Bio-Techne Corp's price target?
Analysts forecast that Bio-Techne Corp's price target is USD 70.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 60.00.
How have Bio-Techne CorpTECH's recent earnings per share performed?
The market expectation was USD 0.33, while Bio-Techne CorpTECH's earnings per share (EPS) for the previous quarter was USD 0.24. EPS for the next quarter is expected at USD 0.52.
What is the analyst rating for Bio-Techne Corp?
Based on the ratings of Bio-Techne Corp's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
